This test examines key genetic variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313markers that influence how your body processes semaglutide and tirzepatide
33 In this respect, its effects parallel those of IGF-1 and IGF-2
Case Reports and Additional Evidence A case report published in Neuro-Ophthalmology described a 73-year-old man with type 2 diabetes, obesity, and hypertension who developed bilateral NAION after significant weight loss and postural hypotension while on semaglutide
What if Im already taking GLP-1 medication
Our primary outcomes included percent weight reduction, the proportion achieving at least 15% weight loss, rates of treatment discontinuation, and gastrointestinal adverse events
Semaglutide injection site reactions: what to do Ready to take the next step